A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中蛋白含量越高，其发展成心脏病的可能越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白质组领域内,疾病蛋白质组学在医学和生物药方面具有发现新分子药靶、生物标志物的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发以及正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前研究表明人血液中蛋白含量越高，其发展成心可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白质组领域内,疾蛋白质组学在医学和生物药方面具有发现新分子药靶、生物标志物巨大潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神炎，多发性硬化以及正常人血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神炎，多发性硬化一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中蛋白含量越高，其发展成心脏病的可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白质组领域内,疾病蛋白质组学在医学和药方面具有发现新分子药靶、标志的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经，多发性硬化以及正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经，多发性硬化的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中蛋白含，其发展成心脏病的可能性。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白质组领域内,疾病蛋白质组学在医学和生物药方面具有发现新分子药靶、生物标志物的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发性硬的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中含量越高，其发展成心脏的可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能质组领域内,疾质组学在医学和生物方面具有发现新分、生物标志物的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬化以及正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发性硬化的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中蛋越高，其发展成心脏病的可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋质组领域内,疾病蛋质组学在医学和生物药方面具有发现新分子药靶、生物标志物的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬化以人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，多发性硬化的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

前的研究表明人的血液中蛋白含量越高，其发展成心脏病的可性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功蛋白质组领域内,疾病蛋白质组学在医学和生物药方面具有发现新分子药靶、生物标志物的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，多发性硬化以及正常人的血清进行NMO-IgG测定，判断NMO-IgG是否鉴别视神经脊髓炎，多发性硬化的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中蛋白含量越高，其脏病的可能性越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白质组领域内,疾病蛋白质组学在医学和生物药方面具有现新分子药靶、生物标志物的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓，性硬化以及正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓，性硬化的一项实验室依据。

A seperates separate study found no support for a series theory that a biomarker called C-reactive protium protein causes heart disease.

早前的研究表明人的血液中蛋白含量越高，其心脏病的可能越高。

In the field of functional proteomics,the human disease proteomics shows great potential in the discovery of new molecular targets and biomarkers for medicine and biopharmacy.

其中,在功能蛋白质组领域内,疾病蛋白质组学在医学和生物药方面具有现新分子药靶、生物标志物的巨大的潜力。

In the second part, we detected serum NMO-IgG of patients with neuromyelitis optica, multiple sclerosis and health people to verify whether NMO-IgG can be a biomarker for neuromyelitis optica.

第二部分对视神经脊髓炎，硬化以及正常人的血清进行NMO-IgG测定，判断NMO-IgG是否能作为鉴别视神经脊髓炎，硬化的一项实验室依据。